Abstract 1666P
Background
The GARIBALDI study investigated the impact of oncology center volume, type, and accrual rate on the prognosis of the overall therapeutic management of patients (pts) with non-metastatic Pancreatic Ductal Adenocarcinoma (nmPDAC).
Methods
Consenting treatment-naïve pts ≥ 18-year with pathological diagnosis of nmPDAC were eligible. Participating centers were categorized according to the self-declared expertise, the type and the accrual rate. Survival curves were estimated by the Kaplan–Meier method and compared by the log-rank test. Overall Survival (OS) was defined as the time from the date of medical therapy start to death for any cause.
Results
Between July 2017 and October 2019, 402 pts with nmPDAC from 44 centers were enrolled. Median age was 69 (range 36-89); 50% females; 93% ECOG PS 0-1; 33% overweight/obese; 17%, 38.7%, 44.3% with stage I, II, III, respectively; median CA19.9 177 (range 0-350,933); 17% with prior cancer history. Median diagnosis to treatment interval was 26 days. 68.4% had baseline CT >25 days before treatment start. 64% received chemotherapy upfront mainly consisting of nab-paclitaxel+gemcitabine (55%), gemcitabine alone (12%) or FOLFIRINOX (27%); 50% were submitted to surgery; 32% received radiotherapy. The median follow-up was 43.7 months and 274 pts died. The table provides the median OS estimates.
Table: 1666P
Deaths/N | Overall survival (Median [95%CI]) | Log-rank p-value | |
Self-declared expertise | 0.0036 | ||
Low-volume (<25 pts/year) | 46/61 | 15.5 [11.7-21.8] | |
Medium-volume (25-50 pts/year) | 48/69 | 21.6 [16.9-24.5] | |
High-volume (>50 pts/year) | 174/260 | 23.2 [19.2-27.1] | |
Type | 0.0714 | ||
Community hospitals | 108/154 | 20.6 [16.6-23.2] | |
Academic centers | 166/248 | 22.0 [18.7-26.9] | |
Accrual rate | 0.0238 | ||
Low-accrual (<10 pts/year) | 114/161 | 18.7 [15.8-23.6] | |
Medium-accrual (10-50 pts/year) | 107/149 | 21.6 [18.6-25.1] | |
High-accrual (> 50 pts/year) | 53/92 | 29.3 [18.1-35.6] |
Conclusions
A statistically significant difference in OS was found based on center volume and accrual rate, while a clinical difference was highlighted based on center type.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Associazione Italiana di Oncologia Medica (AIOM).
Funding
Celgene S.r.l.
Disclosure
C. Pinto: Financial Interests, Institutional, Funding: Eli Lilly, Bayer, Roche; Financial Interests, Personal, Advisory Board, DSMB: BMS, Eli Lilly, Novartis and Merck; Financial Interests, Personal, Advisory Board: Novartis, BMS, Amgen. M. Milella: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Pfizer, Merck, Novartis, Ipsen, Viatris; Financial Interests, Personal, Steering Committee Member: Novartis; Financial Interests, Institutional, Funding: Roche. F. Bergamo: Financial Interests, Personal, Invited Speaker: Lilly, BMS, MSD, EISAI, Bayer; Financial Interests, Personal, Advisory Board: Servier, AAA; Other, Other, congress: Bayer, Ipsen, AAA. M.C. Di Marco: Financial Interests, Personal, Advisory Board, DSMC: OncoSil. G.G. Cardellino: Financial Interests, Personal, Other, Attending Meeting and/or travel: Incyte, Eli Lilly, Amgen, MSD; Financial Interests, Personal, Advisory Board: Eli Lilly, MSD, AstraZeneca. L. Cavanna: Financial Interests, Personal, Other, Consulting fees: AstraZeneca, Merck; Financial Interests, Personal, Other, Support for attending meetings and/or travel: Pfizer, Ipsen, Celgene. E. Giommoni: Financial Interests, Personal, Invited Speaker: Viatris, Amgen, AstraZeneca; Financial Interests, Personal, Advisory Board: Viatris, Amgen, Viatris, Ipsen. M. Reni: Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Personal, Advisory Board, and DSMC: Eli Lilly, Panavance, Celgene, AstraZeneca, Viatris, Merck Sharp & Dohme, Servier, Sotio, Baxter. All other authors have declared no conflicts of interest.
Resources from the same session
1654P - Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Presenter: Natalia Gutierrez Alonso
Session: Poster session 22
1655P - Nampt inhibitors re-sensitize MAP17 expressing pancreas tumors
Presenter: Julia Martinez Perez
Session: Poster session 22
1656P - Targeting NPC1L1 rescues anti-tumor immunity and improves immunotherapeutic efficacy in pancreatic cancer
Presenter: Houjie Liang
Session: Poster session 22
1657P - Understanding the role of SAGA and mediator in the resistance to Pdk1 deletion in PDAC
Presenter: Katarina Ondrejkova
Session: Poster session 22
1658P - Molecular subtyping of familial pancreatic ductal adenocarcinoma identifies novel pathogenic germline variants
Presenter: Julie Earl
Session: Poster session 22
1659P - The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
Presenter: Octave Letissier
Session: Poster session 22
1660P - Squalene epoxidase promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signalling pathway
Presenter: Ruiyuan Xu
Session: Poster session 22
1661P - Precision medicine for pancreatic cancer: A clinical study validating EUS biopsies
Presenter: Joanne Lundy
Session: Poster session 22
1662P - Targeting stress granule formation as a synthetic lethality strategy for kras-induced pancreatic cancer initiation
Presenter: Patricia Santofimia
Session: Poster session 22
1663P - Role of next-generation sequencing somatic assays in patients with advanced pancreatic cancer
Presenter: Rafaela Naves
Session: Poster session 22